In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death. Vaccines against both viruses, however, have been difficult to design. Now, scientists have analyzed the structure and stability of a critical RSV and hMPV protein to better design vaccines that target it.
Read more …Researchers use biophysics to design new vaccines against RSV and related respiratory viruses

A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies.
Read more …Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly...

More Articles …